Conditions: Hepatitis C Virus
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 512
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether BMS-790052 added to Peginterferon Alfa-2a and ribavirin can result in higher cure rates in patients who previously failed therapy and may have limited response to retreatment with Peginterferon Alfa-2a and ribavirin alone.

Detailed description:

Arms:
arm 1: (prior null responders) arm 2: (prior null responders) arm 3: (prior partial responders) arm 4: (prior partial responders) arm 5: (prior partial responders only)

Interventions: intervention 1: BMS-790052 intervention 2: BMS-790052 intervention 3: Placebo intervention 4: peginterferon alfa-2a intervention 5: ribavirin
Intervention descriptions: intervention 1: Film coated tablet, Oral, 20 mg, once daily, 24 weeks intervention 2: Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks intervention 3: Film coated tablet, Oral, 0mg, Once daily, 24 weeks intervention 4: Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks intervention 5: Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks

Protocol document: